Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FavID (Favrille, Inc.)
- Development stage
- Discontinued
- Lead developer
- Favrille
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
FavID (also known as Id/KLH) is an autologous active immunotherapy (vaccine) developed by Favrille for the treatment of B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The therapy is personalized for each patient by harvesting the unique immunoglobulin idiotype (Id) protein from their tumor cells and conjugating it to Keyhole Limpet Hemocyanin (KLH), a highly immunogenic carrier protein. This conjugate acts as a patient-specific antigen intended to stimulate a cytotoxic T-lymphocyte and humoral immune response against the malignant B-cell clone. In clinical trials, FavID was typically administered subcutaneously in conjunction with sargramostim (GM-CSF) to enhance dendritic cell recruitment and antigen presentation. Development was halted after a pivotal Phase 3 trial (the STELLAR study) failed to demonstrate a significant improvement in time to progression for patients with DLBCL.
- Brand names
- FavID
- Other names
- autologous immunoglobulin idiotype-KLH conjugate vaccineFavID vaccine
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on FavID (Favrille, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FavID (Favrille, Inc.).